NCT04552730View on ClinicalTrials.gov

Nerve Growth Factor for the Treatment of Cornea Disease

CompletedOBSERVATIONAL
Enrollment

5

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

May 4, 2021

Study Completion Date

May 4, 2021

Conditions
Neurotrophic Keratitis
Interventions
DRUG

Cenegermin-Bkbj

Topical Cenegermin-bkbj 6 times per day for 8 weeks.

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT04552730 - Nerve Growth Factor for the Treatment of Cornea Disease | Biotech Hunter | Biotech Hunter